Fate Therapeutics
Stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Launch date
Employees
Market cap
€387m
Enterprise valuation
€201m (Public information from Sep 2024)
Share price
$4 FATE
San Diego California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 31.4m | 55.8m | 96.3m | 63.5m | 11.3m | 3.9m | 4.8m |
| % growth | 194 % | 78 % | 72 % | (34 %) | (82 %) | (66 %) | 23 % |
| EBITDA | (126m) | (216m) | (308m) | (175m) | (187m) | (204m) | (223m) |
| % EBITDA margin | (400 %) | (386 %) | (320 %) | (275 %) | (1656 %) | (5263 %) | (4685 %) |
| Profit | (173m) | (212m) | (282m) | (161m) | (187m) | (221m) | (246m) |
| % profit margin | (552 %) | (380 %) | (293 %) | (253 %) | (1655 %) | (5686 %) | (5160 %) |
| EV / revenue | 237.0x | 89.0x | 5.7x | 0.8x | 11.6x | 53.1x | 36.5x |
| EV / EBITDA | -59.3x | -23.1x | -1.8x | -0.3x | -0.7x | -1.0x | -0.8x |
| R&D budget | 126m | 216m | 320m | 173m | - | - | - |
| R&D % of revenue | 400 % | 386 % | 333 % | 272 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | $173m | Post IPO Equity |
* | N/A | $201m | Post IPO Equity |
* | N/A | $432m | Post IPO Equity |
* | N/A | N/A | Private Placement VC |
* | $100m | Post IPO Equity | |
| Total Funding | €82.9m | ||
Related Content
Recent News about Fate Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.